Company Profile

FirstString Research Inc (AKA: FSR)
Profile last edited on: 4/5/2019      CAGE: 4GLF5      UEI: T4JKC8B27PJ7

Business Identifier: Breakthrough therapies for inflammation and injury based medical conditions
Year Founded
First Award
Latest Award
Program Status
Active (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

300 West Coleman Boulevard Suite 203
Mount Pleasant, SC 29464
Location: Single
Congr. District: 01
County: Charleston

Public Profile

FirstString Research Inc was acquired in 2016 by Swiss firm Relief Therapeutics Holding AG (SIX: RLF) a Swiss-based publicly-traded drug development company focusing primarily on the clinical development of peptides and proteins of natural or engineered origin to address unmet medical needs. Fairly active ithe SBIR space, FirstString Research (FSR) had functioned as a biotechnology company organized primarily around therapies for scar prevention and tissue regeneration. Pioneering the translation of cell-cell communication and contact/adhesion science into medical applications, FirstString's products included a topical gel for the prevention of scarring resulting from surgeries and injuries. Therapies modulate intercellular communication to reduce the development of scar tissue, as well as improve the body’s ability to produce healthy and functional cells. The Company had an exclusive worldwide license from the Medical University of South Carolina (MUSC) for the connexin-technology platform and intellectual properties of a portfolio of peptides capable of modulating junctional proteins that are critical for inter-cellular communication. A Phase I human clinical trial demonstrated safety and efficacy of a lead peptide generated from the technology platform. The Company also advanced GranexinTM Gel, a topical formulation of the lead peptide, through three Phase II human clinical trials for scar reduction and treatment of chronic wounds.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Key People / Management

  Gautam Sudhir Ghatnekar -- Founder, President and ceo

  Tuan A Elstrom -- Vice President of Business Development

  Gautam Sudhir Ghatnekar

  Robert G Goudie -- Founder

  Christina Grek -- Director of Translational Research

  Steven Holshouser -- Head of Discovery

  Samy Lamouille

  Howard Levinson